stockrow
Friday 6 November 2026
Export BNTX’s income statement to Excel — free account
BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
86.78
0.92
+1.07%
Follow BNTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.99 | 7.81 | 7.05 | 7.09 | |
P/FCF ratio |
0.00 | 47.08 | 39.95 | 0.00 | |
P/Operating CF |
(169.50) | 1,525.76 | (45.68) | 66.76 | |
P/B ratio |
1.20 | 1.14 | 1.03 | 1.06 | |
Price to Tangible BV |
1.32 | 1.27 | 1.15 | 1.18 | |
EV/Sales |
2.95 | 2.24 | 1.80 | 2.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(29.05) | 8.91 | 6.78 | 12.56 | |
EV/FCF |
(15.36) | 13.49 | 10.17 | (19.85) | |
Quick Ratio |
8.43 | 7.70 | 8.64 | 7.40 | |
Current Ratio |
8.55 | 7.85 | 8.80 | 7.54 | |
Net Debt/EBITDA |
(31.54) | 21.18 | 25.78 | 73.50 | |
Debt/Assets |
1.78% | 1.55% | 1.44% | 1.22% | |
Debt/Equity |
0.02 | 0.02 | 0.02 | 0.01 | |
Asset Turnover |
0.11 | 0.13 | 0.14 | 0.13 | |
Operating CF/Net income |
(0.68) | (0.02) | 0.79 | (0.92) | |
Capex/Depreciation |
(0.14) | (0.19) | (0.64) | (0.25) | |
Interest Coverage |
15.06 | (120.01) | (60.49) | (68.85) | |
Research and Development Expense of Revenue |
58.03% | 521.78% | 471.63% | 59.99% | |
Selling, General and Administrative Expense of Revenue |
13.85% | 187.31% | 127.69% | 25.42% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
1.21% | 7.35% | 17.53% | 1.84% | |
Graham Net Nets |
0.62 | 0.63 | 0.68 | 0.66 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.96%) | (8.41%) | (6.62%) | (5.50%) | |
Free Cash Flow Yield |
(2.14%) | 2.12% | 2.50% | (1.42%) | |
Revenue per Share |
5.95 | 0.48 | 0.55 | 4.07 | |
Operating CF per Share |
(0.58) | 0.06 | (1.95) | 1.43 | |
Capex per Share |
(0.21) | (0.24) | (0.36) | (0.18) | |
Free Cash Flow per Share |
(0.79) | (0.18) | (2.30) | 1.24 | |
Cash per Share |
67.67 | 67.83 | 67.65 | 69.64 | |
Shareholders Equity per Share |
81.76 | 81.50 | 86.41 | 89.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
81.76 | 81.50 | 86.41 | 89.99 | |
Free Cash Flow |
(197.18) | (44.42) | (583.21) | 300.71 | |
Working Capital |
15,930.99 | 15,519.84 | 16,112.66 | 15,844.46 | |
Capital Expenditures |
(52.58) | (59.87) | (90.47) | (43.97) | |
Net Current Asset Value |
15,206.66 | 14,780.47 | 15,397.20 | 15,140.62 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.49 | 0.65 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
908.29 | 952.71 | 888.76 | 1,371.67 | |
Average Payables |
534.71 | 662.14 | 508.11 | 533.46 | |
Average Inventory |
169.26 | 189.43 | 194.75 | 215.90 | |
Average Assets |
24,082.83 | 24,107.67 | 23,490.40 | 24,628.65 | |
Average Common Equity |
20,992.15 | 20,826.82 | 20,911.54 | 21,377.51 |
Columns are period end dates · fundamentals updated 5 Nov 2026